Galera Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.galeratx.com
Clinical Trials
21
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05412472
- Locations
- 🇺🇸
Inventiv Health Clinical -Research Pharmacy Unit, Miami, Florida, United States
🇺🇸University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
- Conditions
- SBRTBorderline Resectable Pancreatic CancerUnresectable Pancreatic Cancer
- Interventions
- Drug: Drug GC4711Drug: Placebo
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT04698915
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Miami, Miami, Florida, United States
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04555096
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Saint Louis University, Saint Louis, Missouri, United States
🇺🇸Mercy Research, Saint Louis, Missouri, United States
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
- Conditions
- Head and Neck CancerOral Mucositis
- Interventions
- Radiation: Intensity-modulated radiation therapy (IMRT)
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04529850
- Locations
- 🇧🇪
Onze-Lieve-Vrouwziekenhuis (OLVZ) - Campus Aalst, Aalst, Belgium
🇧🇪AZ Klina, Brasschaat, Belgium
🇧🇪Az Nikolaas, Sint-Niklaas, Belgium
Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC
- Conditions
- SBRTNSCLCNon-metastatic
- Interventions
- Drug: Placebo +SBRTDrug: GC4711 +SBRT
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT04476797
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center at NCMC, Greeley, Colorado, United States
🇺🇸Banner McKee Medical Center, Loveland, Colorado, United States
🇺🇸IACT Health, Columbus, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- Next